IRVINE, Calif. & AMSTERDAM--(EON: Enhanced Online News)--Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today that the MammaPrint® and BluePrint® tests will be highlighted in nine scientific presentations at the upcoming 2016 San Antonio Breast Cancer Symposium (SABCS).
“Long-term follow-up of early stage breast cancer patients with results of MammaPrint, Oncotype DX® and MammoStrat® risk classification assays”
One of the presentations will highlight the long-term outcomes of the use of MammaPrint compared to other breast cancer assays. The study, “Long-term follow-up of early stage breast cancer patients with results of MammaPrint, Oncotype DX® and MammoStrat® risk classification assays” (Shivers, et al.) will be presented on Saturday, December 10th, 2016 at 7:30am – 9:00am in Hall 1.
In addition to the scientific presentations, Agendia will also host two dinner presentations on Thursday, December 8th. The first presentation on “Using Advanced Genomics to Increase Precision Medicine in Breast Cancer Care” will feature William Audeh, MD, Chief Medical Officer at Agendia and Prof. Laura van ’t Veer, PhD, Chief Research Officer at Agendia, and Leader, Breast Oncology Program, and Director, Applied Genomics at UCSF Helen Diller Family Comprehensive Cancer Center.
The second dinner presentation will be held specifically for patient advocates. William Audeh, MD; Dennis Citrin, MB, PhD, Medical Oncologist with Cancer Treatment Centers of America; and Cari Grundman, Patient Advocate Manager with Agendia will discuss their clinical experiences using MammaPrint as well as the clinical trial data behind it.
For more information about either of these events, please inquire at the Agendia conference booth, #155.
MammaPrint is a diagnostic assay that helps predict clinical outcomes in women with early-stage breast cancer, identifying patients who are unlikely to benefit from chemotherapy to spare them from suffering unnecessary side effects and toxicity. It is the only FDA-cleared breast cancer recurrence assay designed for woman of all ages. Unlike other assays with intermediate or indeterminate results, MammaPrint only provides definitive “High Risk” or “Low Risk” results. Furthermore, MammaPrint is supported by the highest level of evidence (Level 1A) from the MINDACT study that was recently published in the New England Journal of Medicine.
MINDACT was a collaboration between Agendia, the European Organization for Research and Treatment of Cancer (EORTC) and the Breast International Group (BIG). A unique phase III prospective, randomized, controlled study of 6,693 patients recruited across 112 European cancer centers, the MINDACT trial showed that 46% of breast cancer patients considered for chemotherapy, whose tumors were classified MammaPrint Low Risk, had excellent survival without chemotherapy, and could thus be candidates to avoid this toxic therapy.
The trial provided the highest level of clinical evidence (Level 1A) and confirmed the clinical utility of using Agendia’s MammaPrint 70-Gene Breast Cancer Recurrence Assay to help predict clinical outcome in women with early-stage breast cancer.
Follow Agendia, Inc. on Facebook, Twitter, or LinkedIn to keep up-to-date with the latest news.
MammaPrint is a FDA-cleared in vitro diagnostic test, available from FFPE sample, performed in a single laboratory, using the gene expression profile of breast cancer tissue samples to assess a patients' risk for distant metastasis. The MammaPrint result is indicated for use by physicians as a prognostic marker only, along with other clinical-pathological factors. MammaPrint is not intended for diagnosis, or to predict or detect response to therapy, or to help select the optimal therapy for patients. Results should be taken in the context of other relevant clinical-pathological factors and standard practice of medicine.
Agendia is a privately held, leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Our offerings include the FDA-cleared MammaPrint FFPE 70-gene breast cancer recurrence assay as well as BluePrint®, a molecular subtyping assay that provides deeper insight leading to more clinically actionable breast cancer biology. These tests can help physicians assess a patient’s individual risk for metastasis – that is, which patients are more sensitive to chemo, hormonal, or combination therapy, and which patients may not require these treatments and which patients may be treated with other, less arduous and costly methods.
In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology. For more information, visit www.agendia.com.